Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q2 2024 earnings summary

Executive summary

• Operating revenue for H1 2024 rose 2.68% year-over-year to RMB41.04 billion, but net profit attributable to shareholders declined 9.31% to RMB2.55 billion, with net profit after non-recurring items down 9.92%.

• The company focused on digital transformation, product innovation, and international expansion, especially in TCM and herbal tea segments.

• Cash flow from operating activities was negative at RMB2.04 billion, a significant deterioration from the prior year, mainly due to increased cash outflows for raw material and drug purchases.

• A cash dividend of RMB4.00 per 10 shares, totaling RMB650.3 million, representing 25.51% of H1 2024 net profit attributable to shareholders, is proposed.

Financial highlights

• Gross margin decreased by 1.72 percentage points year-over-year to 18.89%.

• Basic and diluted EPS were RMB1.568, down 9.31% year-over-year; EPS after non-recurring items was RMB1.44.

• Weighted average return on net assets (ROE) was 7.04%, down 1.36 percentage points year-over-year.

• Net assets attributable to shareholders increased 3.85% from year-end 2023 to RMB36.26 billion.

• Cash and cash equivalents at June 30, 2024, were RMB14.47 billion, down from RMB19.82 billion at year-end 2023.

Outlook and guidance

• The company will focus on digital transformation, product innovation, and international expansion in H2 2024, strengthening TCM and herbal tea market positions.

• Plans include expanding health product channels, upgrading commerce and medical care segments, and intensifying R&D and digitalization.

• Continued investment in digital economy, supply chain, and risk management.